AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Advancements in CAR-T Therapies for Multiple Myeloma
The chapter explores ongoing clinical trials for CAR-T therapies in earlier lines of therapy for multiple myeloma, showcasing positive results with over 50% reduction in progression risk. It compares CAR-T and Biaspecific antibodies, discussing mechanisms, sequencing strategies, and potential approval timelines. The importance of myeloma specialists in guiding treatment decisions, development of CAR-T with multiple targets, and the progress towards allogeneic CAR-T therapies are also discussed.